- Our Focus
A new era of neurological treatments
Novartis is proud to have served patients in Neuroscience for over 70 years. We strive to identify novel targets using human genetics and experimental medicine, advance clinical trial design and pioneer a new era of scientific advancements. Above all, partnering with patients and doctors in an effort to change the lives of people impacted by neurological and psychiatric conditions is at the core of our mission.
With a "brain in a dish," researchers take on a host of neurological disorders
Multiple sclerosis is a chronic disorder of the central nervous system that disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss. In adults, there are three types of MS: relapsing-remitting MS, secondary progressive MS and primary progressive MS. Approximately 2.3 million people worldwide are affected by MS, of which 3-5% are estimated to be children.
Migraine is a serious neurological condition.It involves recurrent attacks of moderate-to-severe head pain that is typically pulsating and often unilateral, and is associated with nausea, vomiting and sensitivity to light, sound and odors. Migraine causes personal pain, disability and reduced quality of life, and it is a financial cost to society.
Speak Your Migraine
Migraine is one of the top 10 causes of years lived with disability for men and women according to the World Health Organisation.
Speak your migraine is a platform with the key goal to empower patients by fostering a community and enable more productive conversations about migraine with their doctors and families. If you or someone you love is suffering from migraine, encourage them to speak their migraine at our Facebook page (for those outside of the United States).
It is estimated that around 44 million people globally have Alzheimer's or a related dementia. Alzheimer's disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks of daily living. In most people with Alzheimer's, symptoms first appear after age 60. Although treatment can help manage symptoms in some people, currently there is no cure.
Novartis is currently conducting a clinical trial program targeting cognitively healthy individuals at risk to develop symptoms of Alzheimer’s disease.
There are areas of high unmet need for people suffering from neuromuscular conditions such as sarcopenia and hip fracture recovery. Additionally, we are committed to the research of peripheral neuropathic pain, a chronic and debilitating condition.